Popular terms

Autoimmune Disease topics
Autoimmune Disease
Immune Disease
Autoimmune
Autoimmune Diseases
Immune Diseases
Transplant
Infectious Disease
Infectious
Inflammatory Disease
Antagonist
Rheumatoid Arthritis
Proliferative
Nucleotide
Antibodies
Infectious Diseases

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune Disease patents

      

This page is updated frequently with new Autoimmune Disease-related patent applications.




Date/App# patent app List of recent Autoimmune Disease-related patents
08/18/16
20160237168 
 Methods for treating and preventing multiple sclerosis patent thumbnailMethods for treating and preventing multiple sclerosis
We have discovered that lrg-47 (also called p47 gtpase), plays a central role in the pathogenesis of multiple sclerosis, and that inhibition of lrg-47 activity by anti-lrg-47 antibodies or of lrg-47 expression by sirna dramatically reduce the pathology and symptoms of multiple sclerosis. Certain embodiments of the invention are directed to the therapeutic use of anti-lrg-47 antibodies (mouse or rabbit or other antibodies that are humanized or human antibodies to lrg-47, preferably antibodies made against human lrg-47) or sirna or antisense nucleotides that specifically hybridize with the gene or mrna or cdna encoding human lrg-47 to treat or prevent multiple sclerosis and other autoimmune diseases that are t-cell-mediated.
The Trustees Of Columbia University In The City Of New York


08/18/16
20160237154 
 Antibody therapeutics that bind ctla4 patent thumbnailAntibody therapeutics that bind ctla4
There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.


08/18/16
20160237075 
 Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease patent thumbnailSubstituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
And pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by bruton's tyrosine kinase (btk).. .

08/18/16
20160235872 
 Compositions and methods to image and quantify inflammation patent thumbnailCompositions and methods to image and quantify inflammation
Compositions and methods for assessing inflammation in a subject. The preset disclosure provides compositions for labeling leukocytes with a 19f-containing perfluoropolyether molecule ex vivo.
Celsense, Inc.


08/18/16
20160235683 
 Amorphous magnesium-substituted calcium phosphate compositions and their uses patent thumbnailAmorphous magnesium-substituted calcium phosphate compositions and their uses
Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium-substituted calcium phosphate to cells of the immune system, for example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.. .
Medical Research Council


08/11/16
20160229900 
 Engineered cxcl12 alpha locked dimer polypeptide patent thumbnailEngineered cxcl12 alpha locked dimer polypeptide
The present invention provides a novel cxcl12-α2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and hiv/aids.. .
The Rockefeller University


08/11/16
20160229892 
 Cyclic peptide conjugates and methods of use patent thumbnailCyclic peptide conjugates and methods of use
The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).. .
Modulation Therapeutics


08/11/16
20160229868 
 Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity patent thumbnailNovel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
A novel fused pyrimidine derivative has an inhibitory activity for tyrosine kinases. A pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases contains the fused pyrimidine derivative as an active ingredient..
Hanmi Science Co., Ltd


08/11/16
20160229860 
 Bicyclic alkyne derivatives and uses thereof patent thumbnailBicyclic alkyne derivatives and uses thereof
The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the map kinase interacting kinases mnk2a, mnk2b, mnk1a, and mnk1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune diseases, metabolic diseases, and neurodegenerative diseases (e.g.
Agency For Science, Technology And Research


08/11/16
20160229843 
 Aza-heteroaryl compounds as pi3k-gamma inhibitors patent thumbnailAza-heteroaryl compounds as pi3k-gamma inhibitors
And pharmaceutically acceptable salts thereof, wherein x, y, z, a, w, r4, r5, and r6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (pi3kγ) and are useful in the treatment of diseases related to the activity of pi3kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .

08/11/16
20160228561 

Protein-cell conjugate, preparation method and use thereof


The present invention pertains to immunology, biomedicine field, specifically relates to a protein-cell conjugate, which is characterized in that the protein and the cell are coupled via a bifunctional cross-linking agent. The present invention further relates to a preparation method and uses of the protein-cell conjugate.
Cansbio (beijing) Biotechnology Co., Ltd.


08/11/16
20160228442 

Nitrogen-containing bicyclic aromatic heterocyclic compound


On the basis of a cathepsin s inhibitory effect, an excellent agent for treating or preventing autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like is provided. It was found that a nitrogen-containing bicyclic heterocyclic compound has an excellent cathepsin s inhibitory effect, thereby completing the invention.
Astellas Pharma Inc.


08/11/16
20160228434 

Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor


An hdac6 inhibitor (a compound of formula i) is shown to reduce the pathogenesis associated with the b cell mediated autoimmune disease, systemic lupus erythematosus (sle) administration of a compound of formula i attenuated many of the symptoms characteristic of sle including splenomegaly, abnormal b cell differentiation, an increase in the number double-negative thymic t cells, an increase in the level of auto-antibodies such as anti-dsdna, immune complex-mediated glomerulonephritis and an increase in inflammatory cytokine production. Treatment with a compound of formula i also increased the number of the subject's splenic treg cells while removing circulating auto-antibodies inhibition of hdac6 altered bone marrow b cell differentiation by increasing the percentage of cells in the early-stage developmental fractions of both pro- and pre-b cells.
Virginia Tech Intellectual Properties, Inc.


08/04/16
20160222113 

Antibodies against pd-1 and uses thereof


The present invention provides antibodies and antigen-binding fragments that specifically bind pd-1 (programmed death 1), thereby modulating immune responses in general, and those mediated by tcr and cd28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer and other immune system disorders..
Medimmune Limited


07/28/16
20160215042 

Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins


Described herein are novel compositions comprising mt1 and/or mt2 modulators (i.e., inhibitors or activators), and methods using these agents for targeting different t-cell populations, for example, type 1 regulatory (tr1) cd4+ cells and exhausted cd8+ t-cells cells. Aspects of the invention relate to inhibitors of mt1 and/or mt2 to increase the differentiation of cd4+ cell trl1 cd4+ cells and increase in the activity of tr1 cells, e.g., to increase il-10 production.
The Brigham And Women's Hospital, Inc.


07/28/16
20160214994 

Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof


Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula i, pharmaceutically acceptable salt, hydrate, solvate, and an optical isomer or prodrug of the compound.
Shanghai Yingli Pharmaceutical Co., Ltd


07/28/16
20160214986 

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


Wherein r1a, r1b, r2, r4, r5, r6, r7, r8, w, x, y, z, cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention..

07/28/16
20160214963 

Inhibitors of bruton's tyrosine kinase


Wherein r0, r1, r2, r3, r4, r5, and l are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds..

07/28/16
20160214951 

Ebi2 modulators


Provided herein are small molecule epstein-barr virus-induced g-protein coupled receptor 2 (ebi2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. Ebi2 is a therapeutic target for the treatment of a variety of diseases or conditions.
Sanford-burnham Medical Research Institute


07/28/16
20160214948 

Prodrugs of monomethyl fumarate (mmf)


The present invention relates to novel compounds for use as a medicament. In particular, the present invention relates to a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis..
Ratiopharm Gmbh


07/28/16
20160213676 

Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis


The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc


07/28/16
20160213666 

Novel compound useful for the treatement of degenerative and inflammatory diseases


A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..

07/28/16
20160213651 

Pidotimod for use in the treatment of inflammation-associated diseases


The present invention relates to a novel use of the active ingredient pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation of the non canonical nfkb pathway, such as allergic diseases, autoimmune diseases or other inflammatory diseases based on mechanisms different from allergic or autoimmune.. .
Polichem S.a.


07/28/16
20160213627 

Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis


The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc


07/21/16
20160208217 

Method for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases


A method for enhancing the therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises pre-treating the stem cells with ligustilide to increase the expression of differentiation-promoting genes in the stem cells, increase the expression of homing-promoting genes in the stem cells, and/or decrease the expression of inflammatory genes in the stem cells, wherein the treatment is conducted in a culture medium of the stem cell..
Gwo Xi Stem Cell Applied Technology Co., Ltd.


07/21/16
20160208013 

Methods and compositions for reducing cardiac damage and other conditions


Endoglin has been identified to play a functional role as a regulator of tgfβ1 signaling, particular in tgfβ1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity.
Tufts Medical Center, Inc.


07/21/16
20160208010 

Anti-human cd52 immunoglobulins


The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human cd52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain.
Genzyme Corporation


07/21/16
20160206756 

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein


The present application describes a coding nucleic acid sequence, particularly a messenger rna (mrna), comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g.
Curevac Ag


07/21/16
20160206660 

Composition of stem cells having highly expressed fas ligand


This disclosure relates in general to a stem cell treatment. This disclosure further relates to a stem cell treatment using a composition comprising stem cells having highly expressed fas-l.
University Of Southern California


07/21/16
20160206611 

Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.


07/14/16
20160201133 

Methods of monitoring conditions by sequence analysis


There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using dna sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions.
Adaptive Biotechnologies Corp.


07/14/16
20160200807 

Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use


The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided.
Chugai Seiyaku Kabushiki Kaisha


07/14/16
20160200789 

Il4 conjugated to antibodies against extracellular matrix components


A conjugate comprising interleukin-4 (il4) and a specific binding member is disclosed. The specific binding member preferably binds an extra-cellular matrix component associated with neoplastic growth and/or angiogenesis, and the conjugate may be used for targeting il4 to tissues in vivo.
Philogen S.p.a.


07/14/16
20160200730 

Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors


Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are bruton's tyrosine kinase (btk) inhibitors.
Zhejiang Dtrm Biopharma Co. Ltd.


07/14/16
20160200710 

Carbazole carboxamide compounds


Disclosed are compounds of formula (i); and salts thereof, wherein: formula (ii); q is: r1 is —c(ch3)2oh, —nhc(=0)c(ch3)3, —n(ch3)2, or —ch2rd; r2 is ci or —ch3; r3 is h, f, or —ch3; ra is h or —ch3; rb is h, f, ci, or —och3 rc is h or f; and rd is —oh, —och3, —nhc(=0)ch3, or formula (iii), also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease..
Bristol-myers Squibb Company


07/14/16
20160200674 

Ido inhibitors


There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (ido), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.. .
Bristol-myers Squibb Company


07/14/16
20160199346 

Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof


The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.. .
Orbital Atk, Inc.


07/07/16
20160194712 

Mirna based treatment monitoring in autoimmune diseases


The invention relates to methods of determining whether a patient responds to a therapeutic treatment of an autoimmune disease, of monitoring the course of an autoimmune disease in a patient, of determining the risk for a relapse of an autoimmune disease in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of an autoimmune disease in a patient. Said methods are based on the determination of the level of at least one mirna in a test sample isolated from the patient.
Comprehensive Biomarker Center Gmbh


07/07/16
20160194642 

Spherical nucleic acid-based constructs as immunoregulatory agents


Aspects of the invention relate to nanoscale constructs and related methods and compositions thereof. The compositions of the invention are useful for treating disorders that are sensitive to levels of immune cell activation, such as autoimmune disease or other inflammation based disease or disorder..
Exicure, Inc


07/07/16
20160194367 

Immunogenic peptides and their use in immune disorders


The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a t-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class ii major histocompatibility complex (mhc) determinant and recognised by cd4+ t cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence.
Katholieke Universiteit Leuven


07/07/16
20160194366 

Applications of an immune system-released activating agent (israa)


The present invention relates to applications of an immune system-released activating agent (israa) polypeptide, which is induced by a nervous stimulus and which has been found to mediate the transmission of signals between the immune system and the nervous system following an immune challenge. The israa polypeptide is for use in a method of treatment of patients with immunodeficiency, immunosuppression or autoimmune disease; cancer; neurologic diseases and disorders; or muscular diseases and disorders..
Arabian Gulf University


07/07/16
20160194338 

Substituted tetrahydrocarbazole and carbazoles carboxamide compounds


R1 is f, cl, —cn, or —ch3; r2 is c1 or —ch3; r3 is —c(ch3)2oh or —ch2ch2oh; ra is h or —ch3; each rb is independently f, cl, —ch3, and/or —och3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

07/07/16
20160194308 

Novel piperidinyl benzoimidazole derivatives as mpges-1 inhibitors


The compounds 1-(5-chloro-6-methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1h-benzo[d]imidazol-2-yl)-n-((3s,4r)-4-hydroxytetrahydrofuran-3-yl)piperidine-4-carboxamide and 1-(6-chloro-5-methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1h-benzo[d]imidazol-2-yl)-n-((3s,4r)-4-hydroxytetrahydrofuran-3-yl)piperidine-4-carboxamide, as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising any one of these compounds. The compound are useful for the treatment and/or prevention of a disorder selected from an inflammatory disease; an autoimmune disease; pain; a breathing disorder; cancer; a cardiovascular disease; a neurodegenerative disease; a bone disease; a disorder due to familial adenomatous polyposis (fap) condition; overactive bladder; fever; and inflammation-related anorexia..
Novasaid Ab


07/07/16
20160193350 

Phosphorylcholine conjugates and uses thereof


The present invention provides phosphorylcholine (pc)-conjugates and pharmaceutical compositions, particularly vaccines comprising same for the prevention or treatment of autoimmune diseases. In particular, the pc-conjugates of the present invention are effective in preventing or treating autoimmune diseases associated with pathological inflammation..
Tel Hashomer Medical Research Infrastructure And Services Ltd.


07/07/16
20160193257 

Human-derived bacteria that induce proliferation or accumulation of regulatory t cells


Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
School Corporation, Azabu Veterinary Medicine Educational Institution


07/07/16
20160193256 

Human-derived bacteria that induce proliferation or accumulation of regulatory t cells


Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
School Corporation, Azabu Veterinary Medicine Educational Institution


06/30/16
20160187351 

Method for the absolute quantification of naturally processed hla-restricted cancer peptides


The present invention relates to a method for the absolute quantification of naturally processed hla-restricted cancer peptides, i.e. The determination of the copy number of peptide(s) as presented per cell.

06/30/16
20160186178 

Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use


Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof. The compositions of the invention are useful for activating agonists of nucleic acid interacting complexes, such as tlrs, stimulating an immune response, and treating diseases such as infectious disease, cancer, allergies, allergic diseases, and autoimmune disease.

06/30/16
20160185857 

Novel anti-fc-gamma receptor iib antibodies and uses thereof


The present invention provides an anti-fcyriib antibodies which, in comparison to prior art antibodies, markedly increase itim phosphorylation of fcyriib and can thus be used for the treatment or prophylaxis of autoimmune diseases.. .

06/30/16
20160185840 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.

06/30/16
20160185771 

Conjugate of benzofuranone and indole or azaindole, and preparation and uses thereof


The present invention relates to an oxo indirubin or isoindigo derivative, an oxo aza indirubin or isoindigo derivative, and their optical isomers, racemes, cis/trans isomers and pharmaceutically acceptable salts, which can be used for preparing a drug for treating or preventing diseases such as glucose metabolic disorder, inflammatory or autoimmune disease, neurodegenerative disease, a mental illness, tissue proliferation disease or tumors.. .

06/30/16
20160185756 

Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists


Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .

06/30/16
20160184329 

Formulations and compositions of vitamin d analogs for treating and preventing cancer and other diseases


This invention is for formulations of analogs of the non-toxic and inert vitamin d3, its non-toxic and mostly inert pre-hormone and its toxic and biologically active hormone, and for using these formulations for preventing and treating certain cancers such as breast, prostate, ovarian, kidney, renal and other cancers, vitamin d deficiency, autoimmune disease such as multiple sclerosis, hypertension, osteoporosis, bone diseases, rickets, psoriasis and infectious diseases. This invention also discloses compositions of the analogs of the non-toxic and inert vitamin d3 and the non-toxic and mostly inert vitamin d3 pre-hormone..

06/23/16
20160176980 

T-cell redirecting bispecific antibodies for treatment of disease


The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.

06/23/16
20160176968 

T-cell redirecting bispecific antibodies for treatment of disease


The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.

06/23/16
20160176965 

Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease


Cytotoxic anti-lag-3 monoclonal antibodies or fragments thereof causing depletion of lag-3+ activated t cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences..

06/23/16
20160176875 

Spirocyclic ebi2 modulators


Provided herein are small molecule epstein-barr virus-induced g-protein coupled receptor 2 (ebi2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, ebi2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease..

06/23/16
20160176849 

N-cyanomethylamides as inhibitors of janus kinase


The present invention relates to compounds of general formula (1) that are inhibitors of janus kinase (jak), a family of tyrosine kinases that are involved in inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons. In particular, the compound of the invention inhibits jak1 and/or jak2 and/or jak3 sub families.

06/23/16
20160175412 

Prevention of type 1 diabetes by treg vaccination with an insulin mimetope


The invention involves methods and products for inducing treg cells for immune suppression in connection with autoimmune disease and transplant rejection.. .

06/23/16
20160175354 

Therapeutic ozone agent and treatment


The use of a medical therapeutic ozone agent in vivo to treat a variety of disorders including, but not limited to hypoxic conditions, autoimmune disease, fibrotic disease, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and vascular disease, metabolic disease, and cancer, wherein the therapeutic ozone agent is administered in a therapeutically effective amount, which can convert carbon monoxide to carbon dioxide and significantly raise systemic oxygen partial pressure to increase the delivery of oxygen to all tissue, systemically, to enable the reversal of hypoxic conditions of the human and animal body and the consequences of those hypoxic conditions, thereby treating or preventing the disease in a patient.. .

06/23/16
20160175353 

Therapeutic ozone agent and treatment


The use of a medical therapeutic ozone agent in vivo to treat a variety of disorders including, but not limited to autoimmune disease, fibrotic disease, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and vascular disease, metabolic disease, cancer, wherein the therapeutic ozone agent is administered in a therapeutically effective amount, which can convert carbon monoxide to carbon dioxide, thereby treating or preventing the disease in a patient.. .

06/23/16
20160175292 

Antioxidants having aromatic structures reacting with superoxide


Disclosed is a method of treating diseases which are: reactive oxygen species mediated, ischemic or reperfusion-related, or t-cell mediated, including autoimmune diseases. The method is administering a therapeutically effective amount of a formulation wherein the active ingredient includes non-phenolic aromatic structures that are electron deficient and are capable of converting the superoxide radical to o2; and/or of converting superoxide radical to oxygen and hydrogen peroxide, or pharmaceutically acceptable salts of said structures.

06/23/16
20160175272 

Compositions and methods for treatment of inflammation


The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response.

06/16/16
20160168254 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/16/16
20160168248 

Regulatory t cell mediator proteins and uses thereof


In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. Multiple sclerosis is disclosed.

06/16/16
20160168149 

Purinone compounds as kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc


06/16/16
20160168083 

Therapeutic compounds


Or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula i, processes for preparing compounds of formula i, intermediates useful for preparing compounds of formula i and therapeutic methods for treating cancer or treating autoimmune diseases or preventing transplant rejection using compounds of formula i..



Autoimmune Disease topics: Autoimmune Disease, Immune Disease, Autoimmune, Autoimmune Diseases, Immune Diseases, Transplant, Infectious Disease, Infectious, Inflammatory Disease, Antagonist, Rheumatoid Arthritis, Proliferative, Nucleotide, Antibodies, Infectious Diseases

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.509

5823

1 - 1 - 107